This post was originally published on this site
Moderna (NASDAQ:MRNA) is said to be evaluating pricing its COVID-19 vaccine between $110 to $130 per dose in the US once it moves from government contracting to commercial distribution, The Wall Street Journal reported Monday.
Moderna Chief Executive Officer Stephane Bancel was said to have revealed the range in an interview on the sidelines of the J.P. Morgan Healthcare Conference in San Francisco. Bancel reportedly said he believes “this type of pricing is consistent with the value.”
The range is similar to the one Pfizer (NYSE:PFE) revealed it was assessing back in October.
However, the potential price represents a significant increase on the per-dose cost in Moderna’s federal government supply contracts, with its updated booster shots costing the government around $26 per dose in a federal supply contract signed in July 2022. The price for the original vaccine was said to be about $15 to $16 per dose in earlier contracts.
So far, the federal government has acquired the COVID-19 vaccines and made them available at no cost, but they said after the supply secured under federal contracts runs out, companies will need to switch to standard commercial distribution.
Bancel said Moderna is in discussions with various outlets regarding the vaccine distribution.
